Brokerages forecast that Mylan NV (NASDAQ:MYL) will report $1.21 earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have made estimates for Mylan’s earnings, with the lowest EPS estimate coming in at $1.15 and the highest estimate coming in at $1.28. Mylan posted earnings per share of $1.10 during the same quarter last year, which would suggest a positive year-over-year growth rate of 10%. The company is scheduled to report its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Mylan will report full year earnings of $4.68 per share for the current fiscal year, with EPS estimates ranging from $4.55 to $4.78. For the next year, analysts expect that the business will report earnings of $5.23 per share, with EPS estimates ranging from $4.90 to $5.54. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Mylan.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, August 8th. The company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.15). The firm had revenue of $2.81 billion during the quarter, compared to analyst estimates of $2.95 billion. Mylan had a net margin of 3.90% and a return on equity of 18.48%. The company’s revenue was down 5.2% on a year-over-year basis. During the same period last year, the company earned $1.10 EPS.

A number of equities analysts have recently issued reports on MYL shares. Guggenheim reissued a “buy” rating and issued a $59.00 target price on shares of Mylan in a report on Wednesday, June 6th. ValuEngine cut Mylan from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. BidaskClub cut Mylan from a “hold” rating to a “sell” rating in a report on Friday, July 13th. Cowen reissued a “hold” rating and issued a $31.00 target price on shares of Mylan in a report on Thursday, August 9th. Finally, Bank of America dropped their target price on Mylan from $43.00 to $42.00 and set a “neutral” rating for the company in a report on Tuesday, May 29th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $46.47.

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its holdings in Mylan by 32.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 9,408,218 shares of the company’s stock valued at $340,012,000 after purchasing an additional 2,284,545 shares in the last quarter. FMR LLC increased its holdings in Mylan by 1.9% during the 2nd quarter. FMR LLC now owns 9,171,840 shares of the company’s stock valued at $331,470,000 after purchasing an additional 168,347 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Mylan by 219.1% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 7,057,501 shares of the company’s stock valued at $290,557,000 after purchasing an additional 4,845,703 shares in the last quarter. FIL Ltd increased its holdings in Mylan by 6.6% during the 1st quarter. FIL Ltd now owns 5,522,241 shares of the company’s stock valued at $227,350,000 after purchasing an additional 343,102 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Mylan by 2.7% during the 2nd quarter. Janus Henderson Group PLC now owns 5,389,463 shares of the company’s stock valued at $194,776,000 after purchasing an additional 144,075 shares in the last quarter. 83.80% of the stock is owned by hedge funds and other institutional investors.

Mylan stock traded up $0.30 during trading hours on Friday, hitting $38.15. The stock had a trading volume of 247,875 shares, compared to its average volume of 4,925,167. The company has a quick ratio of 0.77, a current ratio of 1.29 and a debt-to-equity ratio of 1.18. The stock has a market cap of $19.18 billion, a price-to-earnings ratio of 8.33, a price-to-earnings-growth ratio of 1.16 and a beta of 1.34. Mylan has a fifty-two week low of $29.53 and a fifty-two week high of $47.82.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Recommended Story: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.